|Bid||234.13 x 1000|
|Ask||234.35 x 1400|
|Day's Range||233.16 - 238.70|
|52 Week Range||107.44 - 242.14|
|Beta (5Y Monthly)||0.75|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Dexcom Schedules Fourth Quarter and Full Year 2019 Earnings Release and Conference Call for February 13, 2020 at 4:30 p.m. Eastern Time
Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2019 and Provides Initial 2020 Outlook
DexCom, Inc. (NASDAQ: DXCM), a leader in continuous glucose monitoring (CGM), has partnered with Tandem Diabetes Care in the UK, Sweden, Italy and Spain to distribute the Dexcom G6 CGM System integrated with the Tandem Diabetes Care t:slim X2 insulin pump for people with diabetes.
Eli Lilly and Company (NYSE: LLY) has announced a global commercialization agreement to integrate DexCom, Inc. (NASDAQ: DXCM) products into Lilly's personalized diabetes management system, currently in development to advance the treatment of diabetes. Under the terms of the non-exclusive agreement, Lilly will use Dexcom's continuous glucose monitoring (CGM) devices in both the pen- and pump-based platforms of the system being designed to help improve diabetes management.
DexCom, Inc. today announced that it plans to release its third quarter 2019 financial results after market close on Wednesday, November 6, 2019. Management will hold a conference call to review the company's third quarter 2019 performance starting at 4:30 p.m.
VANCOUVER , Sept. 9, 2019 /CNW/ - DexCom Inc. (DXCM), a leader in continuous glucose monitoring (CGM), announced today that it is now accepting orders for the Dexcom G6 CGM System for people with diabetes ages two years and up.
DexCom, Inc. (DXCM) and Companion Medical, Inc. today announced a collaboration to enable a direct exchange of CGM data from Dexcom with insulin data from InPen™ into both companies’ software applications. This agreement is the first of its kind and paves the way for advanced diabetes decision support, an important tool for insulin users. Dexcom and Companion Medical are working together to develop a seamless data transfer of both insulin and glucose information.
DexCom, Inc. (DXCM) today announced that it plans to release its first quarter 2019 financial results after market close on Wednesday, May 1, 2019. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com by navigating to “About Us,” then “Investor Relations,” and then “Events and Presentations,” and will be archived there for future reference. DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by people with diabetes and by healthcare providers for the treatment of people with diabetes.
NEW YORK, Feb. 26, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
VANCOUVER , Feb. 22, 2019 /CNW/ - Dexcom, Inc. (DXCM), a leader in continuous glucose monitoring (CGM), today announced that the company has received Health Canada approval for its next generation Dexcom G6 CGM System for people with diabetes ages two years and up. This approval now clears the way for the Dexcom G6 to be made available to Canadians with diabetes.